IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

TINCATI, CAMILLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.277
NA - Nord America 7.756
AS - Asia 6.423
SA - Sud America 723
AF - Africa 193
OC - Oceania 56
Continente sconosciuto - Info sul continente non disponibili 11
Totale 23.439
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.431
GB - Regno Unito 3.153
CN - Cina 1.989
SG - Singapore 1.859
IT - Italia 1.592
DE - Germania 1.204
HK - Hong Kong 638
BR - Brasile 550
RU - Federazione Russa 493
VN - Vietnam 479
BD - Bangladesh 434
SE - Svezia 400
FR - Francia 313
IN - India 284
CA - Canada 240
NL - Olanda 238
FI - Finlandia 202
IE - Irlanda 169
TR - Turchia 144
ID - Indonesia 140
KR - Corea 133
UA - Ucraina 114
JP - Giappone 86
ES - Italia 61
DK - Danimarca 60
MX - Messico 55
BE - Belgio 53
AR - Argentina 52
AU - Australia 51
CI - Costa d'Avorio 50
ZA - Sudafrica 45
PL - Polonia 41
CO - Colombia 40
AT - Austria 39
EU - Europa 38
IQ - Iraq 27
EC - Ecuador 25
CH - Svizzera 23
TH - Thailandia 23
TW - Taiwan 23
UZ - Uzbekistan 21
PT - Portogallo 20
ET - Etiopia 19
GR - Grecia 19
MA - Marocco 16
MY - Malesia 16
PH - Filippine 16
NO - Norvegia 15
PE - Perù 15
CL - Cile 14
CZ - Repubblica Ceca 12
KE - Kenya 12
PK - Pakistan 12
VE - Venezuela 12
IR - Iran 11
JO - Giordania 10
NP - Nepal 10
SA - Arabia Saudita 9
AE - Emirati Arabi Uniti 8
DZ - Algeria 8
KZ - Kazakistan 8
LB - Libano 7
MK - Macedonia 7
ZM - Zambia 7
ZW - Zimbabwe 7
EG - Egitto 6
IL - Israele 6
LT - Lituania 6
LU - Lussemburgo 6
NG - Nigeria 6
PY - Paraguay 6
UY - Uruguay 6
AL - Albania 5
BG - Bulgaria 5
JM - Giamaica 5
NZ - Nuova Zelanda 5
RO - Romania 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
BY - Bielorussia 4
LV - Lettonia 4
PA - Panama 4
PS - Palestinian Territory 4
GT - Guatemala 3
HR - Croazia 3
KG - Kirghizistan 3
LY - Libia 3
MD - Moldavia 3
MM - Myanmar 3
NI - Nicaragua 3
OM - Oman 3
TN - Tunisia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
CW - ???statistics.table.value.countryCode.CW??? 2
HU - Ungheria 2
LK - Sri Lanka 2
RS - Serbia 2
SC - Seychelles 2
Totale 23.437
Salva come PNG Salva come JPEG
Città #
Southend 2.923
Singapore 1.074
Ashburn 860
Dallas 750
Frankfurt am Main 702
Milan 568
Hong Kong 561
Chandler 437
Fairfield 394
San Jose 392
Beijing 389
Seattle 285
Ann Arbor 234
Council Bluffs 218
Wilmington 218
Los Angeles 217
Woodbridge 194
Hefei 171
New York 169
Dublin 165
Houston 161
Santa Clara 158
Princeton 155
Ho Chi Minh City 148
Jakarta 124
Cambridge 120
Hanoi 120
Dearborn 118
Rome 110
Bengaluru 109
Helsinki 109
Toronto 107
Buffalo 104
Guangzhou 102
Lauterbourg 100
Chicago 89
Moscow 83
The Dalles 82
Boardman 73
Shanghai 73
Nanjing 71
Des Moines 69
Jacksonville 69
Grafing 67
Phoenix 62
Munich 57
Tokyo 55
Hangzhou 51
São Paulo 51
Abidjan 49
Cangzhou 48
Columbus 47
Seoul 45
Nuremberg 44
London 42
Turin 42
Naples 41
Brussels 40
Istanbul 38
Mumbai 38
Redmond 38
Atlanta 34
Montreal 32
Salt Lake City 31
Boston 30
Montréal 29
Shenzhen 29
Tianjin 29
Warsaw 29
Berlin 28
Wuhan 28
Zhengzhou 28
Changsha 27
Orem 27
Redwood City 27
Vienna 27
Bologna 26
Haiphong 26
Shenyang 26
Mountain View 25
Sakarya 25
Bogotá 24
Fremont 24
Ottawa 24
San Diego 24
Washington 24
Amsterdam 23
Andover 23
Jinan 23
Rio de Janeiro 23
Silver Spring 23
Lappeenranta 22
Kiez 21
Elk Grove Village 20
Paris 20
Serra 20
Bangkok 19
Saint Petersburg 19
Tampa 19
Fuzhou 18
Totale 15.206
Salva come PNG Salva come JPEG
Nome #
Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients 812
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 577
Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection 350
Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis 340
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults : results of the "COPA" pilot randomized trial 326
Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression 321
Reduced central memory CD4+ T cells and increased T-Cell activation characterise treatment-naive patients newly diagnosed at late stage of HIV infection 317
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 315
Detection of human papillomavirus in fresh and dried urine through an automated system for cervical cancer screening in low‐ and middle‐income countries 310
Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients 302
Comprehensive management of paranasal sinus fungus balls: a Young‐IFOS consensus statement 302
Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature 294
Subclinical hypothyroidism in HIV-infected subjects 293
Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy 293
Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection 292
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 292
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts : Data from the Icona Foundation Cohort 291
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 286
Invariant Natural Killer T (iNKT) cells in HAART-treated, HIV-positive patients with bone and cardiovascular impairment 284
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression : 48-week efficacy and safety results 283
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 281
Microbial translocation in the pathogenesis of HIV infection and AIDS 278
The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy : clinical risk, immunological gaps, and therapeutic options 274
T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside retrotranscriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study 274
Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocation 272
FoxP3 mRNA Expression in Regulatory T Cells from Patients with Tuberculosis 271
Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes 258
PATHOGENESIS OF POOR IMMUNE RECOVERY ON COMBINATION ANTIRETROVIRAL THERAPY (CART): THE ROLE OF THE GASTROINTESTINAL TRACT AND MICROBIAL TRANSLOCATION 256
Growth Differentiation Factor 15 (GDF-15) Levels Associate with Lower Survival in Chronic Kidney Disease Patients with COVID-19 254
Insulin resistance affects early virologic response in HIV-infected subjects treated for hepatitis C infection 254
Abacavir and cardiovascular risk in HIV-infected patients: does T-lymphocyte hyperactivation exert a pathogenic role? 251
Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy 245
Serum alpha-Fetoprotein levels predict early virologic response in HIV-positive subjects treated for chronic hepatitis C 245
Role of in vitro stimulation with lipopolysaccharide on T-Cell activation in HIV-infected antiretroviral-treated patients 245
Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: A randomized study 244
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 242
Untangling the immunological implications of nadir on CD4+ cell recovery during suppressive highly active antiretroviral therapy 236
Biomarkers of aging in HIV: inflammation and the microbiome 236
Cell-Mediated Immunity in HIV-Infected Males With Human Papillomavirus-Related Anal Dysplastic Lesions 233
Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection 231
Declining mortality rate of hospitalised patients in the second wave of the COVID-19 epidemics in Italy : Risk factors and the age-specific patterns 227
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy : an observational cohort study 226
Discontinuation of initial antiretroviral therapy in clinical practice : Moving toward individualized therapy 226
CD8+ hyperactivation and senescence correlate with early carotid intima-media thickness in HIV+ patients with no cardiovascular disease 222
Sudden cardiac death in a young HIV-positive man on effective antiretroviral therapy 222
Appropriateness for SARS-CoV-2 vaccination for otolaryngologist and head and neck surgeons in case of pregnancy, breastfeeding, or childbearing potential: Yo-IFOS and CEORL-HNS joint clinical consensus statement 221
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients : results from the Icona Foundation study 219
Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients 218
The challenge of IL-2 Immunotherapy in HIV Disease : “No through Road” or turning point? 214
The importance of patients’ case-mix for the correct interpretation of the hospital fatality rate in COVID-19 disease 213
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 212
Treatment interruptions in HIV-infected subjects 209
Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral Therapy 209
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 207
Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness 203
Appropriateness for SARS-CoV-2 Vaccination for Otolaryngologist and Head and Neck Surgeons in case of Pregnancy, Breastfeeding or Childbearing potential: YO-IFOS and CEORL-HNS joint clinical consensus statement 203
Atazanavir/ritonavir monotherapy : 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 202
Persistence of High Percentage of Peripheral Activated CD8+ T Cells Predict Cytologic HPV-Related Dysplasia in cART-Treated, HIV-Positive Subjects 202
Predictors of low ovarian reserve in cART-treated women living with HIV 201
Female gender is associated with long COVID syndrome : a prospective cohort study 199
Clinical effect of interleukin-2 (IL-2) immuno-adjuvant treatment in HIV+ advanced naïve patients 198
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 198
Sequencing of bacterial microflora in peripheral blood: our experience with HIV-infected patients 197
Immunophenotype and function of CD38-expressing CD4+ and CD8+ T cells in HIV-infected patients undergoing suppressive combination antiretroviral therapy 197
Multi-layered deep immune profiling, SARS-CoV-2 RNAemia and inflammation in unvaccinated COVID-19 individuals with persistent symptoms 194
CD57 Expression and Cytokine Production by T Cells in Lesional and Unaffected Skin from Patients with Psoriasis 194
Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19 192
Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects 191
Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames? 188
Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis 188
Reduced CD127 expression on peripheral CD4+ T cells impairs immunological recovery in course of suppressive HAART 188
Immune activation, inflammation and HIV DNA after 96-weeks of ATV/r monotherapy : a MODAt substudy 187
HIV-Related Oral Mucosa Lesions: A Cross-Sectional Study on a Cohort of Italian Patients 187
Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIV 186
Do combination antiretroviral therapy regimens for HIV infection feature diverse T-Cell phenotypes and inflammatory profiles? 180
Disseminated cytomegalovirus disease after bendamustine : a case report and analysis of circulating B- A nd T-cell subsets 178
Immune reconstitution in HIV+ subjects on Lopinavir/Ritonavir-based HAART according to the severity of pre-therapy CD4+ 175
A Comprehensive Ex Vivo Functional Analysis of Human NKT Cells Reveals Production of MIP1-alpha and MIP1-beta, a Lack of IL-17, and a Th1-Bias in Males 174
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives : Data from the ICONA cohort 173
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation 171
Distinguishing Latent from Active Mycobacterium tuberculosis Infection Using Elispot Assays: Looking Beyond Interferon-gamma 170
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced dimalsease: a trial emulation 169
Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients 168
Immunological mechanisms of interleukin-2 (IL-2) treatment in HIV/AIDS disease 163
Performance evaluation of a self-administered point-of-care test for anal HPV screening in PrEP users: data from a community-based PrEP service 152
Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen : Results from an Observational Cohort Study 150
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy : Data from the Icona Foundation cohort 149
Investigating the Interplay of SARS-CoV-2 RNAemia and Peripheral Inflammation in Platelet Dysfunction During Acute SARS-CoV-2 Infection 148
Comparable gut mucosal breakdown and microbial translocation in severe COVID-19 with and without HIV infection 146
Switching from intravenous to oral antibiotic therapy in the treatment of infective endocarditis: a case series and literature review of real-world data 145
Gut-dependent inflammation and alterations of the intestinal microbiota in individuals with perinatal HIV exposure and different HIV serostatus 144
Bone diseases associated with human immunodeficiency virus infection: pathogenesis, risk factors and clinical management 143
HIV screening in the emergency department: an opinion piece by the Italian Societies of Infectious Diseases and Emergency Medicine 139
Three case reports of West Nile virus neuroinvasive disease: lessons from real-life clinical practice 139
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 133
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 132
HIV-Indicator condition guided testing in a hospital setting 126
Shewanella putrefaciens, an emerging foe from climate change: a case report 123
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 122
Proportion of newly diagnosed persons with HIV with HIV-RNA greater than/equal to 500,000 copies/mL in 2018-2023 in Italy: data from the ICONA Foundation Cohort Study 121
Totale 22.833
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.470
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.470
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021303 0 0 0 0 0 0 0 0 0 0 229 74
2021/20221.566 148 148 116 97 100 85 107 123 178 181 68 215
2022/20231.593 156 167 120 198 152 270 44 87 193 21 130 55
2023/20241.718 83 98 90 97 283 111 178 149 73 152 181 223
2024/20253.623 170 304 120 344 220 174 219 274 205 441 480 672
2025/20268.633 769 920 920 695 719 529 1.057 460 787 628 1.149 0
Totale 24.284